Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05556967 · ClinicalTrials.gov registry record · Phase 3
Identification of Surrogate Blood and/or Urine Biomarker for Immulina TM (Trademark) in Normal Humans
A Phase 3 study, sponsored by University of Mississippi Medical Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 20
- Enrollment target
NCT05556967 is a Phase 3 study that has completed, run by University of Mississippi Medical Center. The registered enrollment target is 20 participants.
The verdict
NCT05556967, a Phase 3 study, has completed, sponsored by University of Mississippi Medical Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 20 participants
- Enrollment target
Study Summary
This is a pilot study for identifying plasma and/or urine-derived adherence/surrogate biomarker candidates for verifying Immulina™ ingestion by human volunteers (collected before and after consumption of Immulina™, a natural dietary supplement).
Interventions
- DRUG Immulina
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2023-08-09 |
| Est. Completion | 2023-10-19 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05556967
The ClinicalTrials.gov registry entry for NCT05556967 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Mississippi Medical Center, which has 96 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Immulina is the first listed.
NCT05556967 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05556967 about?
NCT05556967 is a clinical study titled "Identification of Surrogate Blood and/or Urine Biomarker for Immulina TM (Trademark) in Normal Humans". This is a pilot study for identifying plasma and/or urine-derived adherence/surrogate biomarker candidates for verifying Immulina™ ingestion by human volunteers (collected before and after consumption of Immulina™, a natural dietary supplement).
What is the current status of trial NCT05556967?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 20 participants. The study started on 2023-08-09. Estimated completion is 2023-10-19.
What interventions are being tested in trial NCT05556967?
The interventions under investigation include: Immulina (DRUG).
Who is sponsoring clinical trial NCT05556967?
This trial is sponsored by University of Mississippi Medical Center, which has 96 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.